---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041918"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-09-09T14:10:13+00:00"
generated_at: "2026-09-09T14:11:09.292966+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspire-Lakewood (ASBP) approves $10M buyback; DCSC 2025 revenue $209.5M, EBITDA $22.3M

## Summary
- Name changed to Aspire-Lakewood Holdings, Inc. effective Sept 8, 2026; ticker remains ASBP.
- Board authorized $10M common stock repurchase program effective Sept 9, 2026.
- DCSC FY2025 revenue ~$209.5M, Adjusted EBITDA $22.3M; H1 2026 revenue $103.9M, EBITDA $10.5M.
- ~1.5M shares outstanding as of Sept 8, 2026; 2025 Adjusted EBITDA ~$15.00 per share.
- CEO cites strong cash flow and undervaluation; buyback may be open market or private transactions.

## SEC filing metadata
- accession: 0001493152-26-041918
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-09-09T14:10:13+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/0001493152-26-041918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041918
- JSON: https://secwatch.observer/filing/0001493152-26-041918.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041918.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.